等待开盘 02-07 09:30:00 美东时间
+0.040
+3.88%
ALT: 24% | Altimmune shares are trading higher after the FDA granted Breakthrough Therapy Designation for Pemvidutide in MASH. RDHL: 52% | RedHill Expands RHB-102 Clinical Development Addressing GLP-1
01-05 20:44
RHB-1021 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis and gastritis,
01-05 20:15
07:38 AM EDT, 08/26/2024 (MT Newswires) -- RedHill Biopharma (RDHL) said Monday that the US Food and Drug Administration granted orphan drug designation for opaganib as a treatment for neuroblastoma, a type of childhood cancer. Besides accelerated review, the designation provides opaganib a seven-ye...
2024-08-26 19:38
08:04 AM EDT, 08/21/2024 (MT Newswires) -- Redhill Biopharma (RDHL) said Wednesday it has launched Talicia by prescription in the United Arab Emirates to treat H. pylori infections in adults. The company said the launch makes RedHill eligible for additional milestone payments, minimum sales payments...
2024-08-21 20:04
07:44 AM EDT, 08/19/2024 (MT Newswires) -- Redhill Biopharma (RDHL) said Monday that it achieved positive results from multiple in vivo studies conducted by RedHill's partner, Apogee Biotechnology Corporation, supporting the potential clinical use of opaganib for the prevention and therapy of Type 2...
2024-08-19 19:44
08:27 AM EDT, 08/16/2024 (MT Newswires) -- Redhill Biopharma (RDHL) said Friday that it will change the ratio of its American depositary shares to its non-traded ordinary shares to a new ratio of one ADS representing 10,000 ordinary shares from the current ratio of one ADS representing 400 ordinary ...
2024-08-16 20:27